Fierce Pharma August 23, 2024
Ayla Ellison, Kevin Dunleavy

For the last 40 years, when federal legislation was ambiguous or left an administrative gap, courts were required to defer to the interpretation of agencies. This stipulation, called the Chevron deference, gave agencies room to advance their regulatory priorities.

The Supreme Court overturned the doctrine...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Conferences / Podcast, Govt Agencies, Pharma, Pharma / Biotech, Regulations, Trends
Overturning Chevron Doctrine Could Impact Medicare’s Drug Selections For Price Negotiations
Merck Is Paying $588M for Potential Successor to Cancer Drug Juggernaut Keytruda
The financial burden of drug shortages: 7 study takeaways
What Stays True for U.S. Health Care Post #Election2024 (1) – Consumers’ Dissatisfaction with Drug Prices
AI In Healthcare: A New Era Of Personalized Patient Care

Share This Article